TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Unmethylated cystine-guanosine dinucleotide (CpG) motifs are pathogen-associated molecular
patterns (PAMPs) associated with bacterial and viral-derived DNA that activate the innate and
humoral immunity via toll-like receptor 9. This is a randomized controlled pilot study
evaluating the clinical and immune correlates of a seroprotective immune response against a
CpG-adjuvanted vaccine for hepatitis B.